Drug Trial Radar · NCT05181085
Study of NST-6179 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Nov 11, 2021
Primary completion
May 27, 2022
Study completion May 27, 2022
Sponsor
- Lead sponsor
- NorthSea Therapeutics B.V.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.
Conditions
- Short Bowel Syndrome
- Parenteral Nutrition Associated Liver Disease
Interventions
NST 6179Drug
orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
PlaceboDrug
inactive analogue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With AEs and SAEs Following Administration of NST 6179Time frame: From screening to 14 days post final dose, up to 4 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit, Ltd
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.